Alife Health (“Alife”), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), today announced that Paxton Maeder-York has stepped down from his role as Chief Executive Officer to serve on the company's Board of Directors. Melissa Teran, previously the company's Chief Operating Officer and Head of Product, has succeeded Paxton as CEO.

Paxton founded Alife in 2020 and has worked diligently over the past five years to bring the best technologies to IVF patients across the globe. Under his leadership, Alife launched five groundbreaking products and secured over $30 million in funding. After nearly five years as CEO, Paxton is transitioning into a strategic role as a member of the Board of Directors to focus on shaping the company’s long-term strategy.

"Founding Alife has been an incredible journey, and I am deeply proud of what we have accomplished," said Paxton. "I am confident that Melissa will bring the leadership, insight, and experience needed to continue our mission to deliver cutting-edge technology to IVF patients around the world."

As a founding member of Alife, Melissa has played a pivotal role in shaping the company’s product strategy and securing key partnerships. With a proven track record of operational excellence and a deep understanding of Alife’s vision, she is well-positioned to lead Alife into its next phase of growth.

“I am honored and excited to step into the role of CEO at such a pivotal moment for Alife,” said Melissa. “I look forward to building on the strong foundation that we have established and continuing to drive innovation, growth, and success for our customers, partners, and employees.” This leadership transition underscores Alife’s commitment to its vision of developing the best AI-powered software to help clinics optimize their operations to improve outcomes, increase efficiency, and enhance the patient experience. As the company continues to grow and evolve, Alife remains focused on improving IVF for patients through cutting-edge technology.